Literature DB >> 24366197

Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.

Shi-Jun Shan1, Ying Guo.   

Abstract

Sclerosing lipogranuloma is a granulomatous reaction to the injection of a high-viscosity fluid in the tissues for the cosmetic purpose of improving body contour; lesions on the extremities and buttocks are commonly the results of injections of therapeutic agents in oily vehicles. Exenatide, once-weekly injection, is a therapeutic method for patients with type 2 diabetes. Here, we describe a case of exenatide once weekly induced eosinophilic sclerosing lipogranuloma at the injection site of a 62-year-old patient. To the best of our knowledge, the histopathologic features of this adverse event have not been reported in the medical literature.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24366197     DOI: 10.1097/DAD.0000000000000036

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  9 in total

Review 1.  Diabetes mellitus and the skin.

Authors:  E Makrantonaki; D Jiang; A M Hossini; G Nikolakis; M Wlaschek; K Scharffetter-Kochanek; C C Zouboulis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 2.  Adverse Effects of GLP-1 Receptor Agonists.

Authors:  Theodosios D Filippatos; Thalia V Panagiotopoulou; Moses S Elisaf
Journal:  Rev Diabet Stud       Date:  2015-02-10

3.  Late-Onset Complication of Fillers: Paraffinoma of the Lower Eyelids Clinically Mimicking Xanthelasma.

Authors:  Min-Woo Kim; Hyun-Sun Park; Hyun-Sun Yoon; Soyun Cho
Journal:  Ann Dermatol       Date:  2016-11-23       Impact factor: 1.444

4.  Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release.

Authors:  Jung-Woo Ko; Kyung-Duck Park; Young Lee; Jeung-Hoon Lee; Dong-Kyun Hong
Journal:  Ann Dermatol       Date:  2020-04-24       Impact factor: 1.444

5.  Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS.

Authors:  Max Sauter; Philipp Uhl; Jürgen Burhenne; Walter E Haefeli
Journal:  J Pharm Anal       Date:  2020-02-22

6.  Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone.

Authors:  Kayla Riswold; Valerie Flynn
Journal:  JAAD Case Rep       Date:  2018-09-18

7.  HYPOTHYROIDISM COULD BE A POTENTIAL FACTOR TO PROLONG SUBCUTANEOUS NODULES OF EXENATIDE ONCE WEEKLY: A CASE REPORT.

Authors:  Ayako Ito; Akie Kamata; Aya Nozaki; Takao Ando; Atsushi Kawakami
Journal:  AACE Clin Case Rep       Date:  2019-04-25

8.  Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  S Christopher Jones; Debra L Ryan; Valerie S W Pratt; Ali Niak; Allen D Brinker
Journal:  Diabetes Spectr       Date:  2015-11

9.  Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus.

Authors:  A Riederer; E Zini; E Salesov; F Fracassi; I Padrutt; K Macha; T M Stöckle; T A Lutz; C E Reusch
Journal:  J Vet Intern Med       Date:  2015-12-24       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.